thalidomide has been researched along with Agranulocytosis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma." | 9.09 | Thalidomide in patients with advanced multiple myeloma. ( Attal, M; Beris, P; Berthou, C; Duguet, C; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Leyvraz, S; Moreau, P; Payen, C; Yakoub-Agha, I, 2000) |
| "Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma." | 7.73 | Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. ( Bocchia, M; Bucalossi, A; Gozzetti, A; Lauria, F; Mazzotta, S; Pirrotta, MT; Sammassimo, S, 2005) |
| "Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma." | 5.09 | Thalidomide in patients with advanced multiple myeloma. ( Attal, M; Beris, P; Berthou, C; Duguet, C; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Leyvraz, S; Moreau, P; Payen, C; Yakoub-Agha, I, 2000) |
| "Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma." | 3.73 | Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. ( Bocchia, M; Bucalossi, A; Gozzetti, A; Lauria, F; Mazzotta, S; Pirrotta, MT; Sammassimo, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keel, SB | 1 |
| Phelps, S | 1 |
| Sabo, KM | 1 |
| O'Leary, MN | 1 |
| Kirn-Safran, CB | 1 |
| Abkowitz, JL | 1 |
| Mazzotta, S | 1 |
| Gozzetti, A | 1 |
| Pirrotta, MT | 1 |
| Bocchia, M | 1 |
| Sammassimo, S | 1 |
| Bucalossi, A | 1 |
| Lauria, F | 1 |
| Magalini, F | 1 |
| Stella, A | 1 |
| Sansoni, P | 1 |
| Yakoub-Agha, I | 1 |
| Moreau, P | 1 |
| Leyvraz, S | 1 |
| Berthou, C | 1 |
| Payen, C | 1 |
| Dumontet, C | 1 |
| Grosbois, B | 1 |
| Beris, P | 1 |
| Duguet, C | 1 |
| Attal, M | 1 |
| Harousseau, JL | 1 |
| Facon, T | 1 |
1 trial available for thalidomide and Agranulocytosis
| Article | Year |
|---|---|
Thalidomide in patients with advanced multiple myeloma.
Topics: Agranulocytosis; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studie | 2000 |
3 other studies available for thalidomide and Agranulocytosis
| Article | Year |
|---|---|
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion | 2012 |
Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Topics: Aged; Agranulocytosis; Antineoplastic Agents; Female; Humans; Leukocyte Count; Multiple Myeloma; Tha | 2005 |
Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
Topics: Aged; Agranulocytosis; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug | 2008 |